Literature DB >> 34008317

The use of local and nonlocal priors in Bayesian test-based monitoring for single-arm phase II clinical trials.

Yanhong Zhou1, Ruitao Lin1, J Jack Lee1.   

Abstract

Bayesian sequential monitoring is widely used in adaptive phase II studies where the objective is to examine whether an experimental drug is efficacious. Common approaches for Bayesian sequential monitoring are based on posterior or predictive probabilities and Bayesian hypothesis testing procedures using Bayes factors. In the first part of the paper, we briefly show the connections between test-based (TB) and posterior probability-based (PB) sequential monitoring approaches. Next, we extensively investigate the choice of local and nonlocal priors for the TB monitoring procedure. We describe the pros and cons of different priors in terms of operating characteristics. We also develop a user-friendly Shiny application to implement the TB design.
© 2021 John Wiley & Sons Ltd.

Entities:  

Keywords:  Bayes factor; local prior; nonlocal prior; phase II; sequential monitoring

Mesh:

Year:  2021        PMID: 34008317      PMCID: PMC9308506          DOI: 10.1002/pst.2139

Source DB:  PubMed          Journal:  Pharm Stat        ISSN: 1539-1604            Impact factor:   1.234


  48 in total

1.  Determining the effective sample size of a parametric prior.

Authors:  Satoshi Morita; Peter F Thall; Peter Müller
Journal:  Biometrics       Date:  2007-08-30       Impact factor: 2.571

2.  Practical Bayesian guidelines for phase IIB clinical trials.

Authors:  P F Thall; R Simon
Journal:  Biometrics       Date:  1994-06       Impact factor: 2.571

3.  Designs for phase II trials allowing for a trade-off between response and toxicity.

Authors:  M R Conaway; G R Petroni
Journal:  Biometrics       Date:  1996-12       Impact factor: 2.571

4.  BOP2: Bayesian optimal design for phase II clinical trials with simple and complex endpoints.

Authors:  Heng Zhou; J Jack Lee; Ying Yuan
Journal:  Stat Med       Date:  2017-06-07       Impact factor: 2.373

5.  Optimal two-stage designs for phase II clinical trials.

Authors:  R Simon
Journal:  Control Clin Trials       Date:  1989-03

6.  Bayesian hypothesis testing with frequentist characteristics in clinical trials.

Authors:  Hui Quan; Bingzhi Zhang; Yu Lan; Xiaodong Luo; Xun Chen
Journal:  Contemp Clin Trials       Date:  2019-10-24       Impact factor: 2.226

7.  Evaluating the Impact of Prior Assumptions in Bayesian Biostatistics.

Authors:  Satoshi Morita; Peter F Thall; Peter Müller
Journal:  Stat Biosci       Date:  2010-07-01

8.  Optimal two-stage designs for exploratory basket trials.

Authors:  Heng Zhou; Fang Liu; Cai Wu; Eric H Rubin; Vincent L Giranda; Cong Chen
Journal:  Contemp Clin Trials       Date:  2019-06-29       Impact factor: 2.226

9.  Designs for group sequential phase II clinical trials.

Authors:  M N Chang; T M Therneau; H S Wieand; S S Cha
Journal:  Biometrics       Date:  1987-12       Impact factor: 2.571

10.  Evaluation of a multi-arm multi-stage Bayesian design for phase II drug selection trials - an example in hemato-oncology.

Authors:  Louis Jacob; Maria Uvarova; Sandrine Boulet; Inva Begaj; Sylvie Chevret
Journal:  BMC Med Res Methodol       Date:  2016-06-02       Impact factor: 4.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.